Cancer Research UK is the largest single funder of cancer research for children in the country and the launch of the event today demonstrates our total commitment to ensure more children survive cancer with fewer side effects. Royal Aberdeen Children’s Hospital, Royal Hospital for Sick Children, Belfast, Birmingham Children’s Hospital, Royal Hospital for Sick Children, Bristol; Addenbroke Hospital, Cambridge, Children’s Hospital of Wales, Cardiff, Royal Hospital for Sick Children, Edinburgh, Royal Hospital for Sick Children, Glasgow, St James University Hospital, Leeds, Leicester Royal Infirmary, Alder Hey Children’s Hospital, Liverpool, Manchester Royal Hospital for Children, Great Ormond Street Hospital in London, University College London Hospital, Royal Victoria Infirmary in Newcastle, Centre Doctor Regina, Nottingham, John Radcliffe Hospital, Oxford, Sheffield Children’s Hospital, Southampton General Hospital, the Royal Marsden Hospital in Sutton.
– At a meeting in June this year the group of children in the North American Oncology has presented the first results of a randomized clinical trial. In this test group treated with chemotherapy and immunotherapy and other treatments have received immunotherapy. Children who received immunotherapy had a better chance of survival without relapse of neuroblastoma after two years.
Brock added: We worked closely with the doctors involved in the study of the United States in the European study design and we hope that this will lead to another treatment option for children with high-risk neuroblastoma have a better chance of disease return.
The phase III trial, which opens in the UK this month, based on promising early results of a U.S. study * which showed that treatment with immunotherapy – boosting the immune system to fight disease – improving the chances of survival of the disease.
Children in the UK with a form of high-risk neuroblastoma children are set to benefit from a new international clinical trial – funded by Cancer Research UK – using immunotherapy to help prevent disease back.
– Neuroblastoma is a form of childhood cancer that develops from the tissue of the nervous system is not developed. Normally grows in the abdomen, the adrenal glands and nervous tissue in the back of the abdomen.
– The trial will be open to patients who are at high risk neuroblastoma nine months after diagnosis and within four months of the last round of aggressive treatment to control the tumor, which means they have a residual disease – when a small number of cells neuroblastoma remain in the body, while the patient is in remission.
In the U. study, half the children received immunotherapy treatment. The European study will benefit all children receiving immunotherapy, and also try to reduce some of the side effects of treatment observed in the study of the United States.
– All children benefit from this study initially receive all the standard treatments for neuroblastoma, which includes chemotherapy to shrink the tumor and target cells that have spread, surgery to remove as much as possible neuroblastoma, a transplant and radiation therapy .
Professor Peter Johnson, clinical director at Cancer Research UK, said: The neuroblastoma research community across Europe have worked hard to design a test committee funding Cancer Research UK agreed on was the independent world-class standards, we are very pleased to fund this process. This will ensure that all children in the UK that could benefit from this promising new treatment can receive in one of our network of childhood cancer throughout the United Kingdom.
Marquette – Windows on Minnesota, IDS Tower 50 th floor, 710 Marquette Avenue, Minneapolis, MN 55402-2368